LFLing Feng

Ling Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ling Feng has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cerebellar heterogeneity and its impact on PET data quantification of 5-HT receptor radioligands

    by Melanie Ganz, Ling Feng, Hanne Demant Hansen, Vincent Beliveau, Claus Svarer, Gitte M Knudsen, Douglas N Greve

    In the quantification of positron emission tomography (PET) radiotracer binding, a commonly used method is reference tissue modeling (RTM). RTM necessitates a proper reference and a ubiquitous choice for G-protein coupled receptors is the cerebellum. We investigated regional differences in uptake within the grey matter of the cerebellar hemispheres (CH), the cerebellar white matter (CW), and the cerebellar vermis (CV) for five PET radioligands targeting the serotonin system. Furthermore, we evaluated the impact of choosing different reference regions when quantifying neocortical binding. The PET and MR images are part of the Cimbi database: 5-HT1AR ([11C]CUMI-101, n = 8), 5-HT1BR ([11C]AZ10419369, n = 36), 5-HT2AR ([11C]Cimbi-36, n = 29), 5-HT4R ([11C]SB207145, n = 59), and 5-HTT ([11C]DASB, n = 100). We employed SUIT and FreeSurfer to delineate CV, CW, and CH and quantified mean standardized uptake values (SUV) and nondisplaceable neocortical binding potential (BPND). Statistical difference was assessed with paired nonparametric two-sided Wilcoxon signed-rank tests and multiple comparison corrected via false discovery rate. We demonstrate significant radioligand specific regional differences in cerebellar uptake. These differences persist when using different cerebellar regions for RTM, but the influence on the neocortical BPND is small. Nevertheless, our data highlight the importance of validating each radioligand carefully for defining the optimal reference region.


  • Open Access

    A High-Resolution In Vivo Atlas of the Human Brain's Serotonin System

    by Vincent Beliveau, Melanie Ganz, Ling Feng, Brice Ozenne, Liselotte Højgaard, Patrick M. Fisher, Claus Svarer, Douglas N. Greve, Gitte M. Knudsen


  • Open Access

    The Variability of Translocator Protein Signal in Brain and Blood of Genotyped Healthy Humans Using In Vivo 123I-CLINDE SPECT Imaging: A Test–Retest Study

    by Ling Feng, Per Jensen, Gerda Thomsen, Agnete Dyssegaard, Claus Svarer, Lars Vestergaard Knudsen, Kirsten Møller, Carsten Thomsen, Jens Damsgaard Mikkelsen, Denis Guilloteau, et al.

    123I-CLINDE is a radiotracer developed for single photon emission computed tomography (SPECT) and targets the 18 kDa Translocator protein (TSPO). TSPO is upregulated in glial cells and used as a measure of neuroinflammation in a variety of CNS diseases. The aim of this study was to examine the test-retest variability of 123I-CLINDE binding in healthy subjects. Methods SPECT-scans were acquired over 90 mins in sixteen healthy controls (nine females, eight mixed affinity binder (MAB) and eight high affinity binders (HAB) twice with an interval of 35±15 days. Arterial input functions were based on individual blood measurements in eight subjects, and a population-based approach in combination with individual whole-blood time activity curves (TACs) in the other eight subjects. Seven brain volumes of interest were extracted and quantified by standard uptake values (SUVs) and by two-tissue compartment modelling (2TCM) for calculation of distribution volumes (VT). Test-retest variability was measured by percentage difference (PD), the absolute PD, intraclass correlation coefficient (ICC) and coefficient of variation (COV). Results The absolute PD of brain SUV and the VT had similar values. The ICC values were higher for VTs than for brain SUVs, which were both moderate to high, however, lower ICC values were observed when calculated separately for HABs and MABs. Test-retest reproducibility was higher in subjects with immediate centrifugation of blood samples. The population-based method efficiently recovered data with delayed centrifugation. The VT of a 49-year-old male HAB was 7.5±1.4 mL/cm3 compared to 4.6±1.4 mL/cm3 of a gender- and age- matched MAB. The SUV of a 49-year-old male HAB and MAB were 1.03±0.14 g/ml and 0.88±0.15 g/ml, respectively. Conclusions The test-retest reproducibility of 123I-CLINDE is comparable or better than that reported for commonly used PET TSPO tracers. Due to binding of 123I-CLINDE to blood cells and peripheral tissues, SUV is not a sufficient surrogate of VT from 2TCM. The population-adjusted method has the potential to reduce the complexity of blood analyses of TSPO tracers.


  • Open Access

    Design of Infusion Schemes for Neuroreceptor Imaging: Application to [11C]Flumazenil-PET Steady-State Study

    by Ling Feng, Claus Svarer, Karine Madsen, Morten Ziebell, Agnete Dyssegaard, Anders Ettrup, Hanne Demant Hansen, Szabolcs Lehel, Stig Yndgaard, Olaf Bjarne Paulson, et al.

    This study aims at developing a simulation system that predicts the optimal study design for attaining tracer steady-state conditions in brain and blood rapidly. Tracer kinetics was determined from bolus studies and used to construct the system. Subsequently, the system was used to design inputs for bolus infusion (BI) or programmed infusion (PI) experiments. Steady-state quantitative measurements can be made with one short scan and venous blood samples. TheGABAAreceptor ligand [C11]Flumazenil (FMZ) was chosen for this purpose, as it lacks a suitable reference region.Methods. Five bolus [C11]FMZ-PET scans were conducted, based on which population-based PI and BI schemes were designed and tested in five additional healthy subjects. The design of a PI was assisted by an offline feedback controller.Results. The system could reproduce the measurements in blood and brain. With PI, [C11]FMZ steady state was attained within 40 min, which was 8 min earlier than the optimal BI (B/I ratio = 55 min).Conclusions. The system can design both BI and PI schemes to attain steady state rapidly. For example, subjects can be [C11]FMZ-PET scanned after 40 min of tracer infusion for 40 min with venous sampling and a straight-forward quantification. This simulation toolbox is available for other PET-tracers.


  • TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between 123I-CLINDE SPECT, 18F-FET PET, and Gadolinium-Enhanced MR Imaging

    by Per Jensen, Ling Feng, Ian Law, Claus Svarer, Gitte M. Knudsen, Jens D. Mikkelsen, Robin de Nijs, Vibeke A. Larsen, Agnete Dyssegaard, Gerda Thomsen, et al.

    Here we compare translocator protein (TSPO) imaging using 6-chloro-2-(4′-123I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide SPECT (123I-CLINDE) and amino acid transport imaging using O-(2-18F-fluoroethyl)-l-tyrosine PET (18F-FET) and investigate whether 123I-CLINDE is superior to 18F-FET in predicting progression of glioblastoma multiforme (GBM) at follow-up. Methods: Three patients with World Health Organization grade IV GBM were scanned with 123I-CLINDE SPECT, 18F-FET PET, and gadolinium-enhanced MR imaging. Molecular imaging data were compared with follow-up gadolinium-enhanced MR images or contrast-enhanced CT scans. Results: The percentage overlap between volumes of interest (VOIs) of increased 18F-FET uptake and 123I-CLINDE binding was variable (12%–42%). The percentage overlap of MR imaging baseline VOIs was greater for 18F-FET (79%–93%) than 123I-CLINDE (15%–30%). In contrast, VOIs of increased contrast enhancement at follow-up compared with baseline overlapped to a greater extent with baseline 123I-CLINDE VOIs than 18F-FET VOIs (21% vs. 8% and 72% vs. 55%). Conclusion: Our preliminary results suggest that TSPO brain imaging in GBM may be a useful tool for predicting tumor progression at follow-up and may be less susceptible to changes in blood–brain barrier permeability than 18F-FET. Larger studies are warranted to test the clinical potential of TSPO imaging in GBM, including presurgical planning and radiotherapy.


  • In Vivo Quantification of Cerebral Translocator Protein Binding in Humans Using 6-Chloro-2-(4′-123I-Iodophenyl)-3-(N,N-Diethyl)-Imidazo[1,2-a]Pyridine-3-Acetamide SPECT

    by Ling Feng, Claus Svarer, Gerda Thomsen, Robin de Nijs, Vibeke A. Larsen, Per Jensen, Dea Adamsen, Agnete Dyssegaard, Walter Fischer, Per Meden, et al.

    This study provides the first comprehensive quantification of translocator protein (TSPO) binding using SPECT and 6-chloro-2-(4′-123I-iodophenyl)- 3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide (123I-CLINDE) in neurologic patients. 123I-CLINDE is structurally related to well-known PET ligands such as 18F-PBR111 and 18F-DPA-714. Methods: Six patients with cerebral stroke and 4 patients with glioblastoma multiforme (GBM) underwent 150-min dynamic SPECT scans with arterial blood sampling. Four of the patients were rescanned. All patients were genotyped for the rs6971 polymorphism. Volumes of interest were delineated on the individual SPECT scans and the coregistered MR images. Compartmental and graphical models using arterial input or the cerebellum as a reference region were used to quantify 123I-CLINDE binding. Results: Among the 6 models investigated, the 2-tissue-compartment model with arterial input described the time–activity data best. Time–stability analyses suggested that acquisition time should be at least 90 min. Intersubject variation in the cerebellar distribution volume (VT) was clearly related to the TSPO genotype. In the stroke patients the VT in the periinfarction zone, compared with VT in the ipsilateral cerebellum, ranged from 1.4 to 3.4, and in the GBM patients the VT in the tumor, compared with the VT in the cerebellum, ranged from 1.8 to 3.4. In areas of gadolinium extravasation, 123I-CLINDE binding parameters were not significantly changed. Thus, 123I-CLINDE binding does not appear to be importantly affected by blood–brain barrier disruption. Conclusion: As demonstrated within a group of stroke and GBM patients, 123I-CLINDE SPECT can be used for quantitative assessment of TSPO expression in vivo. Because of the absence of a region devoid of TSPO, reference tissue models should be used with caution. The 2-tissue-compartment kinetic analysis of a 90-min dynamic scan with arterial blood sampling is recommended for the quantification of 123I-CLINDE binding with SPECT.


  • Top Cited Papers

    Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data

    by Douglas N. Greve, Claus Svarer, Patrick M. Fisher, Ling Feng, Adam E. Hansen, William Baare, Bruce Rosen, Bruce Fischl, Gitte M. Knudsen


  • No change in [11C]CUMI‐101 binding to 5‐HT1A receptors after intravenous citalopram in human

    by Lars H. Pinborg, Ling Feng, Mette E. Haahr, Nic Gillings, Agnete Dyssegaard, Jacob Madsen, Claus Svarer, Stig Yndgaard, Troels W. Kjaer, Ramin V. Parsey, et al.

    The main objective of this study was to determine the sensitivity of [11C]CUMI-101 to citalopram challenge aiming at increasing extracellular 5-HT. CUMI-101 has agonistic properties in human embryonic kidney 293 cells transfected with human recombinant 5-HT1A receptors (Hendry et al. [2011] Nucl Med Biol 38:273–277; Kumar et al. [2006] J Med Chem 49:125–134) and has previously been demonstrated to be sensitive to bolus citalopram in monkeys (Milak et al. [2011] J Cereb Blood Flow Metab 31:243–249). We studied six healthy individuals. Two PET-scans were performed on the same day in each individual before and after constant infusion of citalopram (0.15 mg/kg). The imaging data were analyzed using two tissue compartment kinetic modeling with metabolite corrected arterial input and Simplified Reference Tissue Modeling using cerebellum as a reference region. There was no significant difference in regional distribution volume or non-displaceable binding potential values before and after citalopram infusion. The mean receptor occupancy was 0.03 (range −0.14 to 0.17). Our data imply that [11C]CUMI-101 binding is not sensitive to citalopram infusion in humans. Synapse, 2012.